title: Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines.
abstract: In breast cancer, neuregulin-1 (NRG1) is known as a ligand for the HER3 receptor, which has no intrinsic tyrosine kinase activity. When activated by NRG1 binding, the HER3 receptor forms a heterodimer with other HER family receptors and mediates downstream signaling pathways, leading to multiple effects including growth, proliferation, decreased apoptosis, cellular migration and angiogenesis. Cancer stem cells (CSCs), a subgroup of cancer cells, are considered to have features of stem cells such as self-renewal ability and pluripotent differentiation into other types of mature cells. This study showed that NRG1 treatment induced CSC characteristics in breast cancer cell lines. Using breast cancer cell lines, MCF-7, SKBr-3 and MDA-MB 468, changes related to CSC characteristics were analyzed. Flow cytometry was used to analyze changes in CSC fractions in multiple cell lines after NRG1 treatment. Western blot analysis and immunofluorescence staining demonstrated the expression of CSC markers. To confirm that NRG1 treatment acts through the HER3 receptor, inhibition studies using small interfering RNA (siRNA) were performed. In MCF-7 and SKBr-3 cells, increases in the CSC fraction and expression of CSC markers were observed after NRG1 treatment. However, MDA-MB 468 cells showed high intrinsic expression of CSC markers and a high cellular fraction of CSCs, and in these cells, NRG1 treatment caused no significant change in CSC characteristics. Inhibition of the HER3 receptor blocked the NRG1-induced CSC characteristics, indicating that NRG1 functions through the HER3 receptor. The results imply the presence of a mechanism by which the HER receptors, activated by NRG1, contribute to the acquisition of CSC-like characteristics in some types of breast cancer.
authors.affiliation: Department of Pathology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Jung-gu, Seoul 100-380, Republic of Korea.
authors.forename: Hoiseon
authors.initials: H
authors.lastname: Jeong
authors.affiliation: Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul 152-703, Republic of Korea.
authors.forename: Jinkyoung
authors.initials: J
authors.lastname: Kim
authors.affiliation: Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul 152-703, Republic of Korea.
authors.forename: Youngseok
authors.initials: Y
authors.lastname: Lee
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul 152-703, Republic of Korea.
authors.forename: Jae Hong
authors.initials: JH
authors.lastname: Seo
authors.affiliation: Department of Pathology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Jung-gu, Seoul 100-380, Republic of Korea.
authors.forename: Sung Ran
authors.initials: SR
authors.lastname: Hong
authors.affiliation: Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul 152-703, Republic of Korea.
authors.forename: Aeree
authors.initials: A
authors.lastname: Kim
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D061986:MCF-7 Cells; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology*; D020890:Neuregulin-1 / Q000378:metabolism*; D020893:Receptor, ErbB-3 / Q000378:metabolism*
chemical_list: C094131:NRG1 protein, human; D020890:Neuregulin-1; C581292:ERBB3 protein, human; D020893:Receptor, ErbB-3